A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non−Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpower030
- Sponsors Roche
- 21 Feb 2019 Planned number of patients changed from 302 to 374.
- 21 Feb 2019 Planned End Date changed from 20 Nov 2024 to 30 Mar 2025.
- 21 Feb 2019 Planned primary completion date changed from 31 Mar 2020 to 30 Mar 2025.